Sarah J Harper

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38
    S J Harper
    Department of Pharmacology, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Essex CM20 2QR, Harlow, UK
    Cell Signal 13:299-310. 2001
  2. ncbi MAPKs: new targets for neurodegeneration
    Sarah J Harper
    Department of Biochemistry and Molecular Biology, Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex CM20 2QR, UK
    Expert Opin Ther Targets 7:187-200. 2003
  3. ncbi Small molecule Trk receptor agonists and other neurotrophic factor mimetics
    Scott J Pollack
    Department of Biochemistry Molecular Biology, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
    Curr Drug Targets CNS Neurol Disord 1:59-80. 2002
  4. ncbi Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons
    James Bilsland
    Merck, Sharp and Dohme Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, United Kingdom
    J Neurosci 22:2637-49. 2002
  5. ncbi CEP-1347 promotes survival of NGF responsive neurones in primary DRG explants
    James G Bilsland
    Department of Biochemistry and Molecular Biology, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK
    Neuroreport 14:995-9. 2003

Detail Information

Publications5

  1. ncbi Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38
    S J Harper
    Department of Pharmacology, Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Essex CM20 2QR, Harlow, UK
    Cell Signal 13:299-310. 2001
    ..We will examine the evidence that these pathways are important in neuronal cell death. Finally we will review the evidence that inhibitors of these pathways have a neuroprotective effect both in vitro and in vivo...
  2. ncbi MAPKs: new targets for neurodegeneration
    Sarah J Harper
    Department of Biochemistry and Molecular Biology, Neuroscience Research Centre, Merck, Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex CM20 2QR, UK
    Expert Opin Ther Targets 7:187-200. 2003
    ..Effects of inhibitors, where available, will be discussed, and potential problems and side effects of kinase inhibitors as therapeutics will be addressed...
  3. ncbi Small molecule Trk receptor agonists and other neurotrophic factor mimetics
    Scott J Pollack
    Department of Biochemistry Molecular Biology, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
    Curr Drug Targets CNS Neurol Disord 1:59-80. 2002
    ..Nevertheless, a small subset of the compounds, acting on intracellular signaling pathways downstream of Trk receptors, shows promise for the future treatment of neurodegenerative diseases...
  4. ncbi Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons
    James Bilsland
    Merck, Sharp and Dohme Neuroscience Research Centre, Terlings Park, Harlow, Essex, CM20 2QR, United Kingdom
    J Neurosci 22:2637-49. 2002
    ..We conclude that MPP+ toxicity in primary dopaminergic neurons involves activation of a pathway terminating in caspase 3 activation, but that other mechanisms may underlie the neurite loss...
  5. ncbi CEP-1347 promotes survival of NGF responsive neurones in primary DRG explants
    James G Bilsland
    Department of Biochemistry and Molecular Biology, Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK
    Neuroreport 14:995-9. 2003
    ..CEP-1347 may be a useful tool to maintain viable DRG explants to allow evaluation of neurite outgrowth promoting compounds and dissection of survival and neurite outgrowth signalling pathways...